CSL BEHRING
CSL Behring is a global biotherapeutics company committed to saving lives & improving the quality of life for people with rare & serious diseases worldwide. In case that an unmet or underserved medical need is identified, CSL Behring endeavor to address it – even though the disease is usually rare & the patient population that benefits is very small. The company responds to human needs, not market size.
ABOUT CSL Behring
CSL Behring offers therapies that are used to treat conditions such as: several coagulation disorders including hemophilia A, B & von Willebrand disease, primary & secondary immune deficiencies including Guillain-Barré syndrome, idiopathic thrombocytopenic purpura & Kawasaki disease, hereditary angioedema type I & II, inherited respiratory disease, neurological disorders such as chronic inflammatory demyelinating neuropathy. The company’s products are also used in cardiac surgery, organ transplantation, burn treatment & to prevent hemolytic diseases in the newborn. CSL Behring is a member of the CSL Group of companies. The parent company, CSL Limited (ASX: CSL), is headquartered in Melbourne, Australia. For more information, visit http://www.cslbehring.com
Number of employees:
12
Turnover:
14.823.597 €
CONTACT
General Manager: Marianna Konstantinidi
Address: 5, Hatziyianni Mexi str., 11528 Athens
- Telephone:+30 210 7255660,1
- Fax:+30 210 7255663
- Website: http://www.cslbehring.gr
- Email: [email protected]